SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008: Cancer Incidence and Mortality Worldwide. Lyon: IARC, 2010. Available at: http://globocan.iarc.fr/. Accessed 25 May 2011
  • 2
    Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008; 148: 43548
  • 3
    Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 6171
  • 4
    Carter HB. Management of low (favourable)-risk prostate cancer. BJU Int 2011; 108: 168495
  • 5
    Huang GJ, Sadetsky N, Penson DF. Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol 2010; 183: 220612
  • 6
    Hegarty J, Beirne PV, Walsh E, Comber H, Fitzgerald T, Wallace Kazer M. Radical prostatectomy versus watchful waiting for prostate cancer. Cochrane Database Syst Rev 2010; (11): CD006590
  • 7
    Albertsen PC. When is active surveillance the appropriate treatment for prostate cancer? Acta Oncol 2011; 50 (Suppl. 1): 1206
  • 8
    Cox J, Amling CL. Current decision-making in prostate cancer therapy. Curr Opin Urol 2008; 18: 2758
  • 9
    Zeliadt SB, Ramsey SD, Penson DF et al. Why do men choose one treatment over another? A review of patient decision making for localized prostate cancer. Cancer 2006; 106: 186574
  • 10
    Branney P, White A, Jain S, Hiley C, Flowers P. Choosing health, choosing treatment: patient choice after diagnosis of localized prostate cancer. Urology 2009; 74: 96871
  • 11
    Singh J, Trabulsi EJ, Gomella LG. The quality-of-life impact of prostate cancer treatments. Curr Urol Rep 2010; 11: 13946
  • 12
    Baade PD, Aitken JF, Ferguson M, Gardiner RA, Chambers SK. Diagnostic and treatment pathways for men with prostate cancer in Queensland: investigating spatial and demographic inequalities. BMC Cancer 2010; 10: 452
  • 13
    Medical Outcomes Trust and Quality Metric Incorporated. SF-36: SF-36v2TM Health Survey. (IQOLA SF36v2 Standard, English (Australia), 7/03). Medical Outcomes Trust and Quality Metric Incorporated, Health Assessment Las: Lincoln, RI, 1992, 2003
  • 14
    Thompson SC, Pitts JS, Schwankovsky L. Preferences for involvement in medical decision-making: situational and demographic influences. Patient Educ Couns 1993; 22: 13340
  • 15
    Australian Bureau of Statistics. Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia. 2006. Canberra: ABS2008. Report No.: Cat. No. 2033.0.55.001
  • 16
    Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 1996; 49: 90716
  • 17
    Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 111723
  • 18
    Jang TL, Bekelman JE, Liu Y et al. Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med 2010; 170: 44050
  • 19
    National Health and Medical Research Council and Australian Cancer Network. Clinical Practice Guidelines: evidence-based information and recommendations for the management of localised prostate cancer. A report of the Australian Cancer Network Working Party on Management of Localised Prostate Cancer. Canberra, 2003
  • 20
    Harlan LC, Potosky A, Gilliland FD et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 2001; 93: 186471
  • 21
    Schymura MJ, Kahn AR, German RR et al. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer 2010; 10: 152
  • 22
    Gwede CK, Pow-Sang J, Seigne J et al. Treatment decision-making strategies and influences in patients with localized prostate carcinoma. Cancer 2005; 104: 138190
  • 23
    Sommers BD, Beard CJ, D'Amico AV, Kaplan I, Richie JP, Zeckhauser RJ. Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 2008; 113: 205867
  • 24
    Baade PD, Steginga SK, Pinnock CB, Aitken JF. Communicating prostate cancer risk: what should we be telling our patients? Med J Aust 2005; 182: 4725
  • 25
    Thompson B, Baade P, Coory M, Carriere P, Fritschi L. Patterns of surgical treatment for women diagnosed with early breast cancer in Queensland. Ann Surg Oncol 2008; 15: 44351
  • 26
    Steenland K, Goodman M, Liff J et al. The effect of race and rural residence on prostate cancer treatment choice among men in Georgia. Urology 2011; 77: 5817
  • 27
    Chu DI, Freedland SJ. Prostate cancer. Socioeconomic status and disparities in treatment patterns. Nat Rev Urol 2010; 7: 4801
  • 28
    PHIAC. Quarterly Statistics: Hospital Treatment, General Treatment. Private Health Insurance Administration Council ed., Barton: Australian Government, 2011. Available at: http://www.phiac.gov.au/resources/file/membershipdata/MC%20Jun11.pdf. Accessed 25 May 2012